JP2020528890A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528890A5
JP2020528890A5 JP2020503013A JP2020503013A JP2020528890A5 JP 2020528890 A5 JP2020528890 A5 JP 2020528890A5 JP 2020503013 A JP2020503013 A JP 2020503013A JP 2020503013 A JP2020503013 A JP 2020503013A JP 2020528890 A5 JP2020528890 A5 JP 2020528890A5
Authority
JP
Japan
Prior art keywords
sequence
modified
nucleic acid
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020503013A
Other languages
English (en)
Japanese (ja)
Other versions
JP7144915B2 (ja
JP2020528890A (ja
Filing date
Publication date
Priority claimed from CN201710600732.8A external-priority patent/CN109276580B/zh
Application filed filed Critical
Publication of JP2020528890A publication Critical patent/JP2020528890A/ja
Publication of JP2020528890A5 publication Critical patent/JP2020528890A5/ja
Application granted granted Critical
Publication of JP7144915B2 publication Critical patent/JP7144915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020503013A 2017-07-21 2018-07-18 腫瘍を治療するためのウイルス Active JP7144915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710600732.8 2017-07-21
CN201710600732.8A CN109276580B (zh) 2017-07-21 2017-07-21 一种用于治疗肿瘤的病毒
PCT/CN2018/096100 WO2019015601A1 (zh) 2017-07-21 2018-07-18 一种用于治疗肿瘤的病毒

Publications (3)

Publication Number Publication Date
JP2020528890A JP2020528890A (ja) 2020-10-01
JP2020528890A5 true JP2020528890A5 (https=) 2020-11-26
JP7144915B2 JP7144915B2 (ja) 2022-09-30

Family

ID=65015869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503013A Active JP7144915B2 (ja) 2017-07-21 2018-07-18 腫瘍を治療するためのウイルス

Country Status (7)

Country Link
US (1) US11793844B2 (https=)
EP (1) EP3656854A4 (https=)
JP (1) JP7144915B2 (https=)
KR (1) KR102566552B1 (https=)
CN (2) CN109276580B (https=)
AU (1) AU2018303064B2 (https=)
WO (1) WO2019015601A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
CN110283794B (zh) * 2019-05-30 2021-04-23 伍泽堂 重组溶瘤病毒以及制备方法、应用和药物
TW202242105A (zh) * 2021-04-17 2022-11-01 景均股份有限公司 Vero細胞適應培養之D68型腸病毒、D68型腸病毒疫苗及其用途
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
EP4604981A2 (en) * 2022-10-19 2025-08-27 KaliVir Immunotherapeutics, Inc. Nucleic acids encoding soluble pd-1 and il-12 and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005221725B2 (en) * 2004-03-11 2010-06-24 Viralytics Limited Modified oncolytic viruses
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
EP2125032A4 (en) * 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
JP2016500108A (ja) 2012-11-21 2016-01-07 デューク ユニバーシティー ヒトの腫瘍のための腫瘍溶解性ポリオウイルス
JP6396891B2 (ja) 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
ES3011466T3 (en) * 2013-04-18 2025-04-07 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
EP2826856B9 (en) * 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
CA2931322A1 (en) * 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
US10752966B2 (en) 2015-04-24 2020-08-25 Washington University Methods and compositions for detection of enterovirus D68
US9938588B2 (en) 2015-06-05 2018-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for detecting Enterovirus D68

Similar Documents

Publication Publication Date Title
JP2020528890A5 (https=)
JP6419706B2 (ja) ミニプロモーターカセットを含むレトロウイルスベクター
Callegari et al. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus
JP2020524993A5 (https=)
JP2021522190A5 (https=)
JP2021514190A (ja) コード化リボ核酸の器官保護発現および調節のための組成物および方法
JPWO2019093435A1 (ja) 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス(腫瘍溶解性免疫治療)
TWI545196B (zh) Reic表現腺病毒載體
JP2023159160A (ja) 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
CN110387353B (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
CN110101862B (zh) 使用smad3抑制剂对癌症的治疗
Qu et al. Inhibitory effect of biosynthetic nanoscale peptide Melittin on hepatocellular carcinoma, driven by survivin promoter
CN115989321B (zh) 病毒制剂、用于配制病毒制剂的溶液及其用途
JP2020537534A5 (https=)
JPWO2019201192A5 (https=)
JP6803619B2 (ja) REIC/Dkk−3遺伝子およびチェックポイント阻害剤を用いた併用療法
US20240076689A1 (en) Viral vectors and nucleic acids for regulated gene therapy
CA2675342C (en) A method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging
JP7699122B2 (ja) 複製促進腫瘍溶解性アデノウイルス
AU2019359505B2 (en) A method to treat disease using a nucleic acid vector encoding a highly compact multi-input logic gate
Plotnikova et al. PRODUCTION AND BIOLOGICAL ACTIVITY OF THE EXOGENOUS mRNA ENCODING HUMAN MxA PROTEIN
RU2551784C1 (ru) Универсальный промотор для экспрессии терапевтических генов в клетках млекопитающих
CN121358860A (zh) 肿瘤特异性表达盒及其用途
JP5713306B2 (ja) ガンのリンパ節転移抑制剤
RU2020100074A (ru) Композиции, содержащие куроны, и пути их применения